Fred D. Lublin, MD

Fred D. Lublin, MD, is the Saunders Family Professor of Neurology and director of The Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Icahn School of Medicine at Mount Sinai in New York, NY. He is also director of the Multiple Sclerosis Fellowship at The Mount Sinai Hospital.

Dr Lublin received his medical degree from Jefferson Medical College in 1972. He completed his internship in internal medicine from the Bronx Municipal Hospital, Albert Einstein Medical Center, and his neurology residency at the New York Hospital, Cornell Medical Center.

As a neuroimmunologist, Dr Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country to be involved with studies of interferon beta-1b, which was approved by the US Food and Drug Administration (FDA) in 1993 to treat the relapsing-remitting form of multiple sclerosis (MS). He has since been involved in the development of nearly all the currently available agents to treat MS. At present, he is involved with several new clinical research protocols on promising agents for treating various aspects of MS.

Dr Lublin received the 2019 June Halper Lifetime Achievement Award from the Consortium of Multiple Sclerosis Centers and the National Multiple Sclerosis Society (NMSS) Hope Award in 2021. He has published numerous scientific articles and is a member of many professional societies and scientific advisory boards. For example, he is a member of the international panel that periodically redefines the diagnostic criteria for MS (ie, the McDonald criteria). He is also chair of the National Institute of Neurological Disorders and Stroke Multiple Sclerosis Common Data Elements Committee and a member of its steering committee. Dr Lublin has served as a consultant to the National Institutes of Health (NIH) and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He was the principal investigator for the NIH-sponsored, multicenter CombiRx trial.

He was chairman of the NMSS (USA) advisory committees on clinical trials of new drugs in MS and research programs. He was also a member of the NMSS National Board of Directors and is past chair of the New York City/Southern New York Chapter of NMSS Clinical Advisory Committee. He was a member of the MS International Federation International Medical and Scientific Board. Dr Lublin and his colleagues at the NMSS have redefined the clinical course definitions of MS, updated in 2014. He has chaired a task force on the ethics of placebo-controlled trials in MS. Finally, he was a co-chief and founding editor of the journal Multiple Sclerosis and Related Disorders.